0001087294-26-000020
SEC filingCumberland Pharmaceuticals Inc. reported a net loss of $2.9 million for fiscal year 2025, with net revenues of $44.5 million. The company experienced an operating loss of $2.8 million, as total costs and expenses of $47.3 million exceeded revenues. Despite the net loss, the company generated positive operating cash flow of $4.9 million, primarily driven by adjustments including $4.1 million in depreciation and amortization and favorable changes in working capital. The balance sheet shows total assets of $76.8 million, with $11.4 million in cash and cash equivalents and total liabilities of $52.3 million. The company's liquidity position appears stable with current assets of $37.1 million exceeding current liabilities of $36.7 million. Key cost drivers included selling and marketing expenses of $19.1 million and general and administrative expenses of $11.9 million.
Cumberland Pharmaceuticals Inc. reported a net loss of $2.9 million for fiscal year 2025, representing a challenging financial performance. The company generated $44.5 million in net revenues but incurred total costs and expenses of $47.3 million, resulting in an operating loss of $2.8 million. The loss before income taxes was also $2.8 million, with a minimal income tax benefit of $40K. The net loss attributable to common shareholders was $2.8 million. The company reported basic and diluted loss per share of -$0.00, with weighted-average shares outstanding of 14.9 million. Despite the net loss, the company generated positive operating cash flow of $4.9 million, indicating some operational efficiency in cash management.
Net revenues for fiscal year 2025 were $44.5 million. The document does not provide segment breakdown, geographic mix, or specific growth drivers for revenue. No prior year revenue figure is provided in the XBRL data or document text, preventing year-over-year comparison. The revenue figure represents the total product and service revenue for the period without further disaggregation in the provided data.
The company reported a gross margin of 84.9%, calculated from $44.5 million revenue and $6.7 million cost of products sold. Operating margin was negative at -6.3%, reflecting the operating loss of $2.8 million. The cost structure shows significant selling and marketing expenses of $19.1 million (42.9% of revenue), research and development expenses of $5.6 million (12.6% of revenue), general and administrative expenses of $11.9 million (26.7% of revenue), and amortization and impairment of $4.0 million (9.0% of revenue). The high operating expenses relative to revenue contributed to the negative operating margin.
The company generated $4.9 million in operating cash flow despite a net loss of $2.9 million, primarily due to $4.1 million in depreciation and amortization expense and favorable working capital changes including a $5.2 million decrease in accounts receivable and a $6.7 million increase in accounts payable. Investing activities used $4.7 million primarily for manufacturing investments ($2.5M) and other investments ($2.0M). Financing activities used $6.7 million mainly for line of credit payments ($10.0M). Free cash flow (operating cash flow minus capital expenditures) was $0.2 million. The balance sheet shows total assets of $76.8 million, including $11.4 million cash, $16.9 million accounts receivable, and $15.5 million total inventories. Total liabilities were $52.3 million, with $36.7 million current liabilities. Shareholders' equity was $24.9 million with an accumulated deficit of $26.8 million.
The provided document content and XBRL data do not include management guidance, strategic priorities, or specific risk factors for future periods. No forward-looking statements, projections, or outlook information is present in the extracted financial data. The analysis is limited to the historical financial results for fiscal year 2025 as presented in the 10-K filing.